AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07.
On June18, 2018, AVEO Pharmaceuticals, Inc. (the “Company”) held its 2018 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on the following proposals:
1. The following nominees were elected to the Company’s Board of Directors for terms expiring at the 2019 annual meeting of stockholders.
| For | Withheld | BrokerNon- Votes | |
|
Mr.MichaelP. Bailey |
49,464,917 | 305,265 | 49,543,430 |
|
Mr.KennethM. Bate |
47,837,807 | 1,932,375 | 49,543,430 |
|
Dr.AnthonyB. Evnin |
49,459,199 | 310,983 | 49,543,430 |
|
Mr.JohnH. Johnson |
48,179,436 | 1,590,746 | 49,543,430 |
|
Dr.RobertC. Young |
49,366,496 | 403,686 | 49,543,430 |
2. A non-binding, advisory proposal on the compensation of the Company’s named executive officers was approved.
|
For: |
48,704,579 |
|
Against: |
783,037 |
|
Abstain: |
282,566 |
|
Broker Non-Votes: |
49,543,430 |
3. The appointment of Ernst& Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December31, 2018 was ratified.
|
For: |
98,604,832 |
|
Against: |
498,600 |
|
Abstain: |
210,180 |
|
Broker Non-Votes: |
About AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15).